Your browser is no longer supported. Please, upgrade your browser.
VNDA Vanda Pharmaceuticals Inc. weekly Stock Chart
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Index- P/E5.17 EPS (ttm)2.14 Insider Own3.70% Shs Outstand53.81M Perf Week-5.88%
Market Cap599.02M Forward P/E290.79 EPS next Y0.04 Insider Trans-9.85% Shs Float52.90M Perf Month-4.41%
Income116.70M PEG- EPS next Q0.06 Inst Own98.00% Short Float8.17% Perf Quarter0.45%
Sales237.50M P/S2.52 EPS this Y343.30% Inst Trans1.81% Short Ratio5.36 Perf Half Y-33.15%
Book/sh7.74 P/B1.43 EPS next Y-84.80% ROA25.60% Target Price15.00 Perf Year-27.40%
Cash/sh5.76 P/C1.92 EPS next 5Y- ROE30.60% 52W Range7.12 - 17.85 Perf YTD-32.66%
Dividend- P/FCF17.41 EPS past 5Y30.80% ROI26.60% 52W High-36.02% Beta0.47
Dividend %- Quick Ratio6.10 Sales past 5Y35.30% Gross Margin89.60% 52W Low60.39% ATR0.63
Employees284 Current Ratio6.10 Sales Q/Q21.60% Oper. Margin10.40% RSI (14)51.90 Volatility4.97% 5.65%
OptionableYes Debt/Eq0.00 EPS Q/Q176.40% Profit Margin49.10% Rel Volume0.80 Prev Close11.05
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout0.00% Avg Volume806.19K Price11.42
Recom2.40 SMA200.20% SMA505.60% SMA200-14.36% Volume325,341 Change3.35%
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Mar-10-10Initiated Hapoalim Outperform $23
May-26-20 07:00AM  Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting PR Newswire
May-21-20 05:08PM  U.S. doctors call for remdesivir data to guide coronavirus treatment Reuters
May-20-20 05:20PM  Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit PR Newswire +6.73%
10:45AM  Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir PR Newswire
May-15-20 11:43AM  1 Pharma Stock to Avoid at All Costs Motley Fool
May-14-20 07:03AM  This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19 Motley Fool
May-13-20 07:00AM  Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome PR Newswire
May-08-20 07:32PM  Edited Transcript of VNDA earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-07-20 11:31AM  Vanda Pharmaceuticals (VNDA) Q1 2020 Earnings Call Transcript Motley Fool
May-06-20 06:45PM  Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates Zacks
Apr-29-20 04:05PM  Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020 PR Newswire
12:34PM  Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-27-20 02:18PM  What Is Vanda Pharmaceuticals's (NASDAQ:VNDA) P/E Ratio After Its Share Price Rocketed? Simply Wall St.
Apr-23-20 09:12AM  Another 140,000 apply for unemployment benefits in D.C., Md. and Va. American City Business Journals
Apr-22-20 01:01PM  Is Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Paid At A Competitive Rate? Simply Wall St.
Apr-21-20 05:14PM  This company gets FDA green light to proceed with study on possible COVID-19 treatment Yahoo Finance Video
Apr-17-20 10:00AM  Company News for Apr 17, 2020 Zacks
08:54AM  Northam requests more federal aid, Montgomery County steps up PPE funding American City Business Journals
Apr-16-20 10:58AM  Vanda Begins Enrollment in Study for Severe Coronavirus Infection Zacks +6.91%
08:09AM  The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant Benzinga
Apr-15-20 04:15PM  Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine PR Newswire -7.79%
04:05PM  Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia PR Newswire
Apr-09-20 07:52AM  The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall Benzinga
Apr-08-20 04:05PM  Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19 PR Newswire
Apr-03-20 02:26PM  These D.C.-area biotech companies are making progress on COVID-19. Heres the latest. American City Business Journals -6.81%
Apr-02-20 01:36PM  Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia PR Newswire +14.08%
Mar-19-20 12:59PM  Vanda Pharmaceuticals hits another snag with FDA American City Business Journals +9.47%
Mar-18-20 02:29PM  Top Biotech Stocks for Q2 2020 Investopedia -6.25%
Mar-10-20 05:13PM  Edited Transcript of VNDA earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents +8.69%
Feb-27-20 05:35PM  Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences PR Newswire
Feb-26-20 03:05PM  Vandas latest study failed. But revenue grew in 2019. American City Business Journals
Feb-25-20 04:13PM  Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis PR Newswire
04:01PM  Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results PR Newswire
Feb-21-20 12:26PM  Should We Be Delighted With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) ROE Of 30%? Simply Wall St. -9.13%
Feb-19-20 07:00AM  Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors PR Newswire
Feb-18-20 08:22PM  Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 PR Newswire +5.28%
Feb-05-20 09:15AM  Vertex (VRTX) Hits 52-Week High, Can the Run Continue? Zacks
Feb-03-20 03:28PM  Court rules against Vanda, in favor of FDA on clinical trials suit American City Business Journals
Jan-31-20 06:24PM  Vanda Pharmaceuticals Comments on Court Ruling PR Newswire
Jan-16-20 02:57PM  Vandas patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat. American City Business Journals
Jan-13-20 02:11PM  Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt® PR Newswire -5.61%
Jan-12-20 03:34PM  3 Small Caps to Consider for Growth GuruFocus.com
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-23-19 02:27PM  Do Vanda Pharmaceuticals's (NASDAQ:VNDA) Earnings Warrant Your Attention? Simply Wall St.
Dec-12-19 05:15PM  Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award PR Newswire
Dec-10-19 09:12PM  Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds In Wait-and-See Mode Insider Monkey
Nov-19-19 07:15AM  Edited Transcript of VNDA earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 04:01PM  Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences PR Newswire
10:04AM  These Stocks Could Bounce High in January and Beyond GuruFocus.com
Nov-14-19 10:35AM  Top Ranked Value Stocks to Buy for November 14th Zacks
Nov-07-19 07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga +10.58%
Nov-06-19 04:01PM  Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results PR Newswire
Oct-31-19 01:25PM  Hedge Funds Have Never Been Less Bullish On Vanda Pharmaceuticals Inc. (VNDA) Insider Monkey
Oct-30-19 04:30PM  Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019 PR Newswire
10:33AM  Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 04:30PM  Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors PR Newswire
Oct-23-19 04:01PM  Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs PR Newswire
Oct-16-19 04:01PM  Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement PR Newswire
Oct-15-19 08:25AM  SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces that Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors; Shareholders Urged to Contact the Firm ACCESSWIRE
Oct-10-19 01:49PM  Volatility 101: Should Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Have Dropped 42%? Simply Wall St.
Sep-25-19 06:18PM  Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study Zacks +5.53%
Sep-11-19 05:20PM  Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies PR Newswire
Sep-04-19 10:55AM  Here's What We Think About Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Pay Simply Wall St.
Aug-28-19 08:02AM  Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates Benzinga
Aug-21-19 11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
07:00AM  Vanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer PR Newswire
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks
Aug-19-19 02:54PM  FDA rejects Vandas drug application for jet lag disorder American City Business Journals
10:06AM  FDA Issues Complete Response For Vanda's Hetlioz In Jet Lag Disorder Benzinga
07:00AM  Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder PR Newswire
Aug-13-19 03:23PM  Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date? Benzinga
Aug-11-19 03:46PM  The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO Benzinga
Aug-09-19 01:35PM  Edited Transcript of VNDA earnings conference call or presentation 31-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 10:20AM  Why Vanda (VNDA) Might be Well Poised for a Surge Zacks
Aug-05-19 03:59PM  Vanda Pharmaceuticals Returns to Profitability in Q2 Motley Fool
02:54PM  Should You Be Worried About Insider Transactions At Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)? Simply Wall St.
Aug-02-19 02:45PM  This D.C. biotech has hit some bumps this year. Its also breaking revenue records. American City Business Journals
Aug-01-19 05:36PM  Here's Why Vanda Pharmaceuticals Stock Soared on Thursday Motley Fool +26.83%
04:13PM  This Medtech's CEO Promised To 'Correct The Course' That Didn't Happen Investor's Business Daily
11:03AM  This Medtech's CEO Promised To 'Correct The Course' That Didn't Happen Investor's Business Daily
05:24AM  Vanda Pharmaceuticals (VNDA) Q2 2019 Earnings Call Transcript Motley Fool
Jul-31-19 06:35PM  Vanda Pharmaceuticals (VNDA) Surpasses Q2 Earnings and Revenue Estimates Zacks
04:01PM  Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results PR Newswire
Jul-29-19 02:19PM  Shareholder Alert: Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors Business Wire
Jul-24-19 10:33AM  Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-23-19 07:26AM  The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation Benzinga
Jul-22-19 04:01PM  Vanda Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019 PR Newswire
03:02PM  FDA points to deficiencies in Vanda's latest drug application American City Business Journals
07:00AM  Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder PR Newswire
Jul-18-19 02:09PM  How Do You Test a New Seasickness Drug? Take Pill, Set Sail Bloomberg
Jul-17-19 03:00PM  Nausea no more? D.C. biotech gets motion sickness drug to next stage. American City Business Journals
Jul-16-19 04:15PM  Tradipitant Effective in Preventing Motion Sickness PR Newswire
03:35PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vanda Pharmaceuticals Inc. VNDA GlobeNewswire
Jul-08-19 10:16AM  Is Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Potentially Underrated? Simply Wall St.
Jun-19-19 09:32PM  Is Vanda Pharmaceuticals Inc. (VNDA) A Good Stock To Buy? Insider Monkey
Jun-18-19 09:50AM  Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference PR Newswire
May-31-19 09:45AM  Vanda Pharmaceuticals Announces Participation at the Jefferies 2019 Global Healthcare Conference PR Newswire
May-22-19 04:01PM  Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019 PR Newswire
May-21-19 11:41AM  Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Will The Growth Last? Simply Wall St. +9.93%
May-09-19 11:48AM  Should Investors Worry Over a Sluggish First Quarter for Vanda Pharmaceuticals? Motley Fool
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly James PatrickEVP & Chief Financial OfficerMar 03Sale10.765,88963,359186,869Mar 04 05:01 PM
Birznieks GuntherSVP, Business DevelopmentMar 03Sale10.665,53558,984159,473Mar 04 05:00 PM
Polymeropoulos Mihael HristosPresident and CEOMar 03Sale10.985,15256,5441,278,999Mar 04 05:02 PM
Williams TimothySVP & General CounselMar 03Sale10.511,23713,00483,040Mar 04 05:03 PM
Williams TimothySVP & General CounselMar 02Sale10.303,14832,43684,277Mar 04 05:03 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale10.5710,428110,2111,284,151Mar 04 05:02 PM
Birznieks GuntherSVP, Business DevelopmentMar 02Sale10.0412,223122,686165,008Mar 04 05:00 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 02Sale10.1912,968132,087192,758Mar 04 05:01 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerMar 02Sale10.181,45014,755165,384Mar 04 05:02 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Sale16.009,467151,4931,234,579Jan 06 05:26 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerJan 02Sale16.061,15518,551166,834Jan 06 05:26 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 02Sale15.944,02064,086205,726Jan 06 05:25 PM
Birznieks GuntherSVP, Business DevelopmentJan 02Sale15.934,02064,021147,231Jan 06 05:25 PM
Polymeropoulos Mihael HristosPresident and CEODec 12Option Exercise10.6585,801913,7811,314,082Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 12Sale16.9870,0361,189,3511,244,046Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Option Exercise10.6589,199949,9691,300,654Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Sale16.9272,3731,224,3771,228,281Dec 13 04:21 PM
DUGAN RICHARD WDirectorAug 26Option Exercise14.7815,000221,70050,770Aug 28 04:30 PM
DUGAN RICHARD WDirectorAug 26Sale14.8515,000222,75035,770Aug 28 04:30 PM
Williams TimothySVP & General CounselAug 14Sale14.692,57537,82957,425Aug 15 04:58 PM